Drug development efforts are focused on targeting various aspects of AD pathology, including reducing β-amyloid production or aggregation, inhibiting tau protein accumulation, modulating neuroinflammation, and promoting synaptic function and neuronal survival. Immunotherapy approaches, such as monoclonal antibodies targeting β-amyloid or tau proteins, are being investigated in clinical trials as potential disease-modifying treatments. Combination therapies targeting multiple pathways involved in AD pathogenesis are also being explored.